Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 10,564 matching trials from the live ClinicalTrials.gov search.

Filters: Cincinnati, Ohio Clear all

Conditions: Carotid Artery Calcification, Carotid Artery Diseases
Interventions: Carotid Intravascular Lithotripsy (IVL); Device
Lead sponsor: Shockwave Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 25
States / cities: Little Rock, Arkansas • Rancho Mirage, California • Sacramento, California + 20 more

Conditions: Hypophosphatasia
Interventions: Asfotase Alfa; Biological
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 12
States / cities: Hartford, Connecticut • Chicago, Illinois • Boston, Massachusetts + 9 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Budesonide/formoterol pMDI, Formoterol Turbuhaler; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 131
States / cities: Birmingham, Alabama • Huntsville, Alabama • Jasper, Alabama + 128 more

Conditions: Depression
Interventions: blood draw; Procedure
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 971 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 52
States / cities: Birmingham, Alabama • Tuscon, Arizona • Little Rock, Arkansas + 46 more

Conditions: Tuberous Sclerosis Complex
Interventions: RAD001, Placebo; Drug
Lead sponsor: Mustafa Sahin; Other
Eligibility: 6 Years to 21 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts • Cincinnati, Ohio

Conditions: Food Allergy
Interventions: ADP101; Biological
Lead sponsor: Alladapt Immunotherapeutics, Inc.; Industry
Eligibility: 4 Years to 57 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 14
States / cities: Mission Viejo, California • Rolling Hills Estates, California • San Diego, California + 11 more

Conditions: Breast Cancer
Interventions: Doxorubicin, Cyclophosphamide, Ixabepilone (Ixempra), Paclitaxel (Taxol); Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older · Female only
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 69
States / cities: Anniston, Alabama • Huntsville, Alabama • Mobile, Alabama + 61 more

Conditions: Obstructive Sleep Apnea
Interventions: Maridebart cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Northridge, California • Rolling Hills Estates, California • Brandon, Florida + 10 more

Conditions: Plaque Psoriasis
Interventions: Etanercept; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 125 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 33
States / cities: Mobile, Alabama • Bakersfield, California • Beverly Hills, California + 26 more

Conditions: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Interventions: Satralizumab, Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 15
States / cities: Birmingham, Alabama • Irvine, California • Aurora, Colorado + 12 more

Conditions: Hypercholesterolemia
Interventions: Lapaquistat acetate and current lipid-lowering treatment, Current lipid-lowering treatment; Drug
Lead sponsor: Takeda; Industry
Eligibility: 8 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Cincinnati, Ohio • Columbus, Ohio

Conditions: Angelman Syndrome
Interventions: obudanersen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years to 50 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 18
States / cities: Los Angeles, California • San Diego, California • Aurora, Colorado + 13 more

Conditions: Lung Transplant
Interventions: Belumosudil, Placebo for Belumosudil; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 11
States / cities: Los Angeles, California • Palo Alto, California • Baltimore, Maryland + 8 more

Conditions: Colon Cancer
Interventions: Bevacizumab, Cetuximab, 5-fluorouracil, Leucovorin, Oxaliplatin; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 10
States / cities: Evansville, Indiana • Louisville, Kentucky • Portland, Maine + 7 more

Conditions: Head and Neck Cancer, Skin Reactions Secondary to Radiation Therapy
Interventions: Biafine cream, quality-of-life assessment, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 0 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 240
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 187 more

Conditions: Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions: AZD9150, MEDI4736, AZD5069, tremelimumab (treme); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 19
States / cities: Birmingham, Alabama • Duarte, California • La Jolla, California + 15 more

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Constipation Predominant Irritable Bowel Syndrome
Interventions: Tenapanor, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 111
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 92 more

Conditions: Bipolar Depression
Interventions: Lumateperone (ITI-007), Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 42
States / cities: Rogers, Arkansas • Cerritos, California • Costa Mesa, California + 39 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec, placebo, liraglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 67
States / cities: Anaheim, California • Concord, California • Escondido, California + 59 more

Conditions: Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS, EBV-Related Non-Hodgkin Lymphoma, EBV Related PTCL, NOS, EBV-Related Hodgkin Lymphoma, EBV-Related PTLD, EBV-Related Lymphoproliferative Disorder
Interventions: Nanatinostat in combination with valganciclovir; Drug
Lead sponsor: Viracta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 17
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 14 more

Conditions: Ulcerative Colitis
Interventions: Mesalamine Once-Daily, Mesalamine Twice-Daily; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 18 Years and older
Enrollment: 1,027 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 233
States / cities: Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 205 more

Conditions: COPD Patients
Interventions: Symbicort, Formoterol turbohaler, Placebo for Symbicort pMDI, Placebo for Formoterol Turbohaler; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 95 Years
Enrollment: 2,026 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 224
States / cities: Andalusia, Alabama • Birmingham, Alabama • Foley, Alabama + 107 more

Conditions: Pulmonary Sarcoidosis
Interventions: XTMAB-16; Drug
Lead sponsor: Xentria, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Denver, Colorado • Chicago, Illinois • Greenville, North Carolina + 2 more

Search by objective public record fields.

Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Carotid Stenting (SKYWARD Trans-Carotid IDE [Investigational Device Exemption] Study)

A Prospective Sub-Study of the Global Hypophosphatasia Registry

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD

Determine The Percentage Of Depressed Outpatients Who Do Not Effectively Metabolize Extended-release Venlafaxine HCl

Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)

Open-label Extension Study of ADP101

A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia

REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer

Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

The Effects of Zidovudine on the Blood of HIV-Infected Patients

A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C

Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression

The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification

An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas

A Comparison of Once a Day Dose Compared to 2 Doses/Day

Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease

An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis